RT Journal Article
SR Electronic
T1 Plasma proteomic profiles of UK Biobank participants with Multiple Sclerosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.25.23293146
DO 10.1101/2023.07.25.23293146
A1 Jacobs, Benjamin M
A1 Vickaryous, Nicola
A1 Giovannoni, Gavin
A1 Proitsi, Petroula
A1 Waters, Sheena
A1 Dobson, Ruth
YR 2023
UL http://medrxiv.org/content/early/2023/11/20/2023.07.25.23293146.abstract
AB Objective We aimed to describe plasma protein biomarkers of Multiple Sclerosis risk and to explore protein biomarkers of disease severity using radiological outcome measures.Methods Multiple Sclerosis cases and controls were identified in UK Biobank, a longitudinal cohort study of ∼500,000 British adults. Plasma proteins were assayed in ∼50,000 UK Biobank participants using the Olink proximity extension assay. We performed case-control association testing to examine the association between 2911 proteins and Multiple Sclerosis, using linear models adjusted for confounding covariates. Associations with radiological lesion burden and brain volume were determined in a subset of the cohort with available magnetic resonance imaging, using normalised T2-hyperintensity volume or whole brain volume as the outcome measure.Results 407 prevalent Multiple Sclerosis cases and 39,979 healthy controls were included. We discovered 72 proteins associated with Multiple Sclerosis at a Bonferroni-adjusted p-value of 0.05, including established markers such as Neurofilament Light Chain and Glial Fibrillary Acidic Protein. We observed a decrease in plasma Granzyme A, a marker of T cell and NK cell degranulation, which was specific to Multiple Sclerosis. Higher levels of plasma proteins involved in coagulation were associated with lower T2 lesion burden and preserved brain volume.Interpretation We report the largest plasma proteomic screen of Multiple Sclerosis, replicating important known associations and suggesting novel markers, such as the reduction in granzyme A. While these findings require external validation, they demonstrate the power of biobank-scale datasets for discovering new biomarkers for Multiple Sclerosis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementBMJ is funded by a Medical Research Council (MRC) Clinical Research Training Fellowship (CRTF) jointly supported by the UK MS Society (BMJ; grant reference MR/V028766/1), and by Barts Charity. The Preventive Neurology Unit is supported by a grant from Barts Charity.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC) as a Research Tissue Bank (RTB) approval. This approval means that researchers do not require separate ethical clearance and can operate under the RTB approval (there are certain exceptions to this which are set out in the Access Procedures, such as re-contact applications).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes